SLC25A37 and benign prostatic hyperplasia: <i>In vitro</i> study confirmed increased expression levels of SLC25A37 and myeloid cells in BPH tissues.<h4>Conclusions</h4>Our integrative analyses revealed SLC25A37 as a novel causal gene in BPH pathogenesis, unveiling potential therapeutic strategies for BPH treatment.